2992

Bacterial receptors to diagnose P. aeruginosa infections

Helman Yael, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Plant Pathology and Microbiology

 

E. coli-Based Biosensor for Rapid Detection of P. aeruginosa in Ear Infections and Other Applications

 

Categories

Bacteria Diagnostic

Development Stage

Prototype Completed, Ongoing Research

Patent Status

Provisional patent application filed

Market

Ear Infection, Cystic Fibrosis, Hospital-Acquired Infections

Highlights

  • Pseudomonas aeruginosa bacteria are common pathogens that are difficult to treat and are therefore critical to diagnose early when involved in infections.
  • The commonly used method for confirming a P. aeruginosa infection is cultural inoculation, which takes 2-3 days to yield results. 
  •  2-Aminoacetophenone (2-AA) is a volatile substance produced by P. aeruginosa bacteria in high concentrations.  Detection of 2-AA using mass spectrometry has proven successful, but the expensive equipment and highly trained personnel involved make this method impractical in the clinic.

Our Innovation

  • We determined through experiments and in silico docking analysis that there is a binding site between 2-AA and a native LuxR receptor from Vibrio fischeri.  Based on this knowledge, we set out to create a biosensor using E. coli harbouring a plasmid encoding LuxR and a reporter luciferase for bioluminescence. 
  • Through mutagenesis we found a LuxR variant with three amino acids mutated (termed m22).  It shows improved binding with 2-AA, yielding a higher specificity (preventing false positives) and a lower detection limit.
  • We have designed a prototype device for detecting P. aeruginosa in pus samples using this novel biosensor.  It is made of three primary components: a simple plastic tube containing the sample, a cap containing the E. coli-based biosensor, and a bioluminescence detector above the cap.  These components are enclosed in a light-sealed aluminium capsule.
  • Our device allows inexpensive detection of P. aeruginosa infection in a matter of hours.
  • Initial tests with pus from otitis externa (outer ear infections) yielded correct diagnosis in 25/26 cases (7 positive, 17 negative).  Only one false negative was reported, which can likely be attributed either to contamination (in the culture used for comparison) or to a rare P. aeruginosa variant that produces less 2-AA. 
  • Other infections of head and neck origin were correctly detected in 16/20 cases (4 positive, 12 negative) with 4 false negatives.  Due to this poorer performance we plan to focus primarily on otitis externa in the short term.

Key Features

P. aeruginosa, Rapid Diagnostics, Biosensors, Ear Infection, Hospital-Acquired Infection

Development Milestones

  • Seeking funding for research to improve efficiency and expand to other applications
  • Seeking industrial collaboration to advance to clinical trials

The Opportunity

  • Between 1 million and 3 million cases of otitis externa in the US annually, 20%-60% of which are caused by P. aeruginosa
  • At least 90% of malignant otitis externa cases, common in diabetic and immunocompromised individuals, are caused by P. aeruginosa
  • Potential applications in cystic fibrosis, otitis media, infected burns, infected catheters, diabetes complications and more

Researcher Information

Yael Helman, PI, HU

Noam Sobel, Full Professor and Head of Neurobiology Department, WIS

 

 

Patent Status

Published 2017-0067894-A1

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608
Contact ME:
Image CAPTCHA